Choroideremia

Choroideremia is a rare, inherited retinal disorder caused by pathogenic variants in the CHM gene, which encodes Rab escort protein 1. The condition typically follows an X-linked pattern and predominantly affects males, while females may be asymptomatic carriers or experience variable retinal findings. Progressive degeneration of the choroid, retinal pigment epithelium, and photoreceptors can lead to night blindness, narrowing of the visual field, and severe vision loss. Clinical management therefore depends on early recognition, genetic confirmation, visual-function monitoring, and coordinated ophthalmic and genetic counseling services.

Care is shifting from symptom-based management toward genetically confirmed, longitudinal disease characterization. Wider use of inherited-retinal-disease panels, targeted CHM testing, multimodal retinal imaging, and standardized functional assessments is improving diagnostic precision and helping distinguish choroideremia from phenotypically similar retinal dystrophies. Patient registries, natural-history studies, remote-support models, low-vision rehabilitation, and genetic counseling are also strengthening continuity of care. At the same time, emerging therapeutic development is increasing the importance of identifying eligible patients before advanced, irreversible photoreceptor loss occurs.

Artificial intelligence can support choroideremia research by detecting and quantifying retinal changes across fundus photography, optical coherence tomography, and fundus autofluorescence images. Automated segmentation may improve measurement consistency, while longitudinal algorithms can help characterize progression and identify suitable participants for observational studies or clinical trials. AI-assisted clinical decision support could also help prioritize referrals for genetic testing and low-vision services. However, limited disease prevalence, heterogeneous imaging protocols, small datasets, and the need for expert validation constrain deployment. Privacy protection, explainability, and avoidance of demographic or device-related bias remain essential.

North America generally benefits from specialized inherited-retinal-disease centers, genetic testing access, and established low-vision services, although coverage and geographic access vary. Europe combines strong ophthalmic expertise with cross-border research networks, while regulatory and reimbursement pathways differ among countries. Asia-Pacific contains advanced specialist capacity in several economies but faces uneven testing availability and substantial rural-access challenges. Latin America is supported by leading urban ophthalmology centers, yet referral delays and affordability barriers remain important. The Middle East is expanding genomic medicine and specialist infrastructure, with access differing across health systems. Africa faces limited inherited-retinal-disease diagnostic capacity in many settings, making clinician education, referral networks, and affordable testing priorities.

ASEAN members show varied readiness for genetic diagnosis, specialist imaging, and rare-disease support, creating opportunities for shared protocols and regional referral pathways. BRICS countries bring substantial clinical, genomic, and research capabilities but differ in funding, access, and data infrastructure. The European Union benefits from collaborative research and rare-disease policy mechanisms, although national reimbursement systems remain distinct. G7 health systems often have advanced subspecialty care and research capacity, with persistent challenges involving equitable access and long-term support. GCC countries are developing genomic and specialist-care capabilities, while NATO members may benefit from broad scientific collaboration and interoperable research practices. Across all groups, coordinated registries and common outcome standards would improve evidence generation.

Australia has specialist retinal services and a strong research environment, with rural access remaining relevant. Brazil and Mexico need broader referral networks, genetic testing access, and public-sector rare-disease support. Canada and the United States have substantial inherited-retinal-disease expertise, though affordability and regional disparities can affect care continuity. China, India, and Russia have expanding ophthalmic and genomic capabilities, alongside considerable variation between metropolitan and non-metropolitan services. France, Germany, Italy, and Spain operate within sophisticated European clinical ecosystems, but reimbursement and referral pathways differ. Japan and South Korea combine advanced imaging and specialist care with opportunities to expand genetic counseling and patient registries. The United Kingdom has established genomic and ophthalmic services, with timely referral and sustained access to specialist monitoring remaining important.

Industry and health-system leaders should prioritize validated pathways for early referral, genetic confirmation, and family counseling; expand access to multimodal imaging and inherited-retinal-disease specialists; and align registries around standardized visual, imaging, and patient-reported outcomes. Partnerships with patient organizations can improve awareness and reduce diagnostic delay. Therapeutic developers should design studies around meaningful functional endpoints, transparent eligibility criteria, and long-term follow-up. Digital tools and AI should be introduced through clinically validated workflows with strong privacy safeguards. Policymakers and payers should address testing, rehabilitation, mobility support, and assistive-technology access as connected elements of choroideremia care.

This executive summary uses a disease-focused synthesis of established clinical, genetic, ophthalmic, and health-system evidence concerning choroideremia. The framework considers causative biology, diagnostic practice, imaging and functional monitoring, patient-support needs, therapeutic-development priorities, artificial-intelligence applications, and regional variation in infrastructure. Regional, group, and country narratives are qualitative and are intended to highlight access conditions, research readiness, and policy priorities rather than quantify commercial opportunity. Interpretations should be validated against current peer-reviewed literature, clinical guidelines, registry evidence, regulatory information, and locally applicable reimbursement policies.

Choroideremia care is progressing toward earlier genetic diagnosis, more consistent retinal monitoring, and research models centered on preserving functional vision. The greatest practical gains will come from connecting ophthalmology, genomics, rehabilitation, patient advocacy, and data science rather than treating them as separate activities. Regional disparities remain significant, particularly in testing, specialist referral, and long-term support. Leaders who invest in interoperable evidence systems, equitable access, validated digital tools, and patient-centered care pathways will be better positioned to translate scientific progress into meaningful outcomes for affected individuals and families.